
Primary HPV screening: The current state of the science - UK

Theresa Freeman-Wang Consultant Gynaecologist and Secretary BSCCP Whittington Health Women's Health London, UK







Disclosures

• No financial relationships or conflict of interest to disclose





HPV primary screening – UK

Talk will cover:

HPV testing –triage and post treatment 'test of cure'Sentinel site ProjectPreliminary FindingsImplementation plan





Triage of Borderline/low grade abnormalities

England, Wales, Northern Ireland Implemented HPV triage in 2012/3

Scotland-did not implement triage so acceptable to refer for colposcopy if: Borderline nuclear change x 3 Low grade dyskaryosis x 2



I.F.C.P.C



Management of BNA/ Low grade Dyskaryosis

If Colposcopy adequate and normal:

Discharge to GP for routine cytology 3-5 years

If Colposcopy Low grade/ biopsy proven CIN 1:

- Repeat cytology, HPV, colposcopy in 12 months
- Community cytology and HPV in 12 months

If Colposcopy High grade:

Treat





Effects of HPV triage on colposcopy

Increase in low grade referrals

workload /capacity issues

Increase in High grade referrals and treatments detection and management of HG disease

earlier

Reduction of follow-ups if pathway followed





Approved HPV platforms in UK

Qiagen Hybrid Capture 2 High-Risk HPV DNA test Abbott RealTime High Risk HPV test Roche Cobas 4800 HPV system Hologic Aptima HPV Assay Hologic Cervista HPV HR test BD Onclarity HPV test Cepheid Xpert HPV assay





HPV Testing in Wales – current status

HPV Test of Cure (Sept 14/Dec 15)

HPV triage of low grade abnormalities (May 16)

Other factors

- Vaccinated women just entering the screening programme
- Cervical smear numbers falling
 - Extended intervals
 - Reduced repeat smears
- Reduced prevalence of CIN in screened population





Scotland

No data – no pilot sites or early implementers.

Several meetings to put together a full business case as instructed by Scottish government.

If approved, will go to full primary HPV implementation





Northern Ireland

Triage and TOC -follow England guidance


Will see how England and Wales get on.

Have established a committee – but will not be implementing HPV primary screening before 2019.





Republic of Ireland: CERVIVA HPV Primary Screening Pilot



ASGP

I.F.C.P.C.



Evidence supporting HPV Primary screening

ARTISTIC (A Randomised Trial in Screening To Improve Cytology) Manchester based trial, ages 20-65

- Evaluated effectiveness of HR HPV screening
- Compared LBC and HPV testing
- Over 3 screening rounds, HPV-PS
 - Showed increased sensitivity to detect CIN 2+
 - Gave longer protection after a negative result





Six English sentinel sites

Initially evaluated HPV triage

For primary HPV screening: Only partial conversion to maintain cytology expertise Local models for conversion to primary HPV screening are variable Different hr-HPV testing platforms Roche – Norwich, Sheffield, Manchester Genprobe – Bristol, Liverpool Abbot – Manchester, London Triage by reflex cytology Thin prep or Surepath




I.F.C.P.C.



Pilot started in April 2013

Algorithms for HPV primary cervical screening currently in use with the primary HPV screening pilot in England





Amendments to Algorithm for primary HPV screening

April 2014 – started referring HPV 16/18 cytology negative to colposcopy at 12 months

April 2015- started referring HR-HPV other cytology negative at 24 months










ASEP


I.F.C.P.C.

Cancer Screening Programmes


HPV Primary Screening Pilot Colposcopy Management Recommendations Algorithm

Version 2.0 January 2015





HPV Primary Screening Pilot Colposcopy Management Recommendations Algorithm



IFCPC2017 World Congress



ASEP

Primary HPV Screening

- All women aged 25 65
- 314,244 women underwent primary HPV testing to Dec 2015
- 651,307 women underwent primary cytology testing to July 2015


• hr-HPV positive rates

- Average 12.7%, range 10.5 15.0%
- HPV 16/18 4.0%
- Age 24-29 27.6%
- Age 50-64 5.5%





Outcome of cytology by hr-HPV genotyping at Sheffield




Infection with multiple hr-HPVs are associated with higher rates of abnormal cytology





Changes in colposcopy referrals in Sheffield

% of women screened referred to colposcopy




Primary hr-HPV screening increases referral to colposcopy by 68%






Changes in colposcopy referrals at Sheffield







Northwick Park (London) experience








Northwick Park (London) experience

6.03

7.18

7 4 4



2016 %	7.41	



5.61

4.85

4.49

IFCPC2017 World Congress

2014 %

2015 %

204604

National implementation of HPV primary screening

Public Health Minister for England announced HPV primary screening will be implemented into English cervical screening programme by 2019 Deciding how best to roll out HPV testing as the primary cervical screening test

Ruth Stubbs, 31 January 2017 - NHS Cervical Screening Programme







Primary HPV screening implementation: Laboratory reconfiguration



Objective	Weight
Quality	18
Staffing Feasibility	15
Effective IT Connectivity	15
Cost of Safe Delivery	15
Linkage to Local Services	10
Delivery During Transition	6
Adequate Clinical Support	6
Service Sustainability	6
Specimen Transport Feasibility	5
Commissioning Feasibility	4
Total	100






Options appraisal for laboratory reconfiguration

Current system 59 laboratories across England

1. Many providers delivering HPV testing and cytology testing (aligns with current cervical screening model).




Option 1. Many providers of HPV testing and cytology screening. Primary HPV testing may be provided by internal cytology, virology or molecular pathology departments. Trusts without HPV testing facilities onsite may deliver HPV testing through a SLA with a central virology laboratory. If HR-HPV is detected a cervical sample will be sent for cytology screening.






Favoured option for laboratory reconfiguration

- 4. Centralisation of HPV testing and cytology testing as a single seamless service, using:
 - a minimum number of 4 to 5 centralised services performing both HPV testing and cytology screening (option 4a)



Option 4a. A minimum number of large centralised HPV testing and cytology testing services, with high-throughput testing for HR-HPV.

a maximum number of 10 to 15 centralised services performing both HPV testing and cytology screening (option 4b)



Option 4b. A maximum number of centralised HPV testing and cytology testing services, with high-throughput testing for HR-HPV.





Future UK-National Screening Committee Decisions

- •Primary HPV Geno-typing,
- Extended screening intervals following Primary HPV testing implementation,
 Screening HPV positive women beyond the age of 65
 Self sampling and how this impacts on coverage
 How to deal with increase in colposcopy workload

Expected decisions Summer 2017





Acknowledgements and thanks

President BSCCP, Consultant Gynaecologist Sheffield Prof. John Tidy Dr. Tanya Levine Consultant Cytologist Northwick Park, London Mrs. Ruth Stubbs **Cervical screening Programme Manager-England** Mr. Simon Leeson QA colposcopist Wales, Secretary EFC **Cervical screening Wales** Dr. Louise Pickford Consultant gynae- oncologist, Northern Ireland Mr. Gary Dorman Prof. Maggie Cruickshank Past President BSCCP, Scotland Dr. Grainne Flannelly Consultant gynae- oncologist, Republic of Ireland



